Other Events ·
Corbus Pharmaceuticals Holdings, Inc. announced positive topline data from the CANYON-1 Phase 1b clinical trial of…
CRBPCorbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. announced positive topline data from the CANYON-1 Phase 1b clinical trial of CRB-913 for obesity treatment on September 14, 2026. The 16-week, double-blind study enrolled 254 participants and demonstrated statistically significant weight loss at all doses compared to placebo. The 60 mg dose achieved a mean weight loss of 5% at week 12 with no evidence of plateauing. CRB-913 exhibited a favorable safety profile with psychiatric adverse events in line with GLP-1 drugs and lower gastrointestinal side effects than oral incretins. Data will be presented at ObesityWeek 2026, and the company expects to initiate a Phase 2 monotherapy study in the first half of 2027. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies for oncology and obesity.